Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.

 
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
Pharmaceutical Executive Europe E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecdigi
 
Survey
We asked over 40 pharma leaders, which country do you think will offer the most significant growth prospects over the next three years?

Brazil 19%
China 57%
Russia 5%
Indonesia 5%
India 14%

Talk to us:
editor@pharmexeceurope.com

Advertise with us: jgray@advanstar.com

22 November, 2011
In this Issue
One in Ten Adults Diabetic by 2030
According to the International Diabetic Federation (IDF), the number of people living with diabetes could rise from 366 million in 2011 to 552 million by 2030, if preventative measures are not considered. Such a dramatic rise equates to three new cases every 10 seconds, or almost 10 million each year... More...
Russia: A Manufacturing Alternative to China and India
Many foreign bio/pharmaceutical companies are starting to invest heavily in Russia under the expectation that the country will remain one of the world's fastest growing drug-manufacturing markets. Bio/pharmaceutical sales are increasing at around three times faster than the country's GDP. By 2016, total revenue in the Russian bio/pharmaceutical market is forecast by market researchers Frost & Sullivan to reach more than $37 billion—that's 2.4 times higher than 2009 levels and equivalent to an annual growth rate of 13.5%..." More...
FDA Approves 35 Novel Medicines in 2011
FDA Commissioner Margaret Hamburg confirms the agency approved 35 novel medicines in fiscal year 2011. Among the approved products were two drugs for late-stage metastatic melanoma and the first drug to treat Hodgkins lymphoma in 30 years. Other approvals included drugs to treat late-stage prostate cancer, thyroid cancer, metastatic breast cancer, and late-stage lung cancer... More...
Indian Clinical Trial Data Questioned
Regarding Targacept's Phase III studies failing to meet its primary endpoint in its TC-5214 investigational compound as an adjunct therapy to an antidepressant compared to placebo, Adam Feuerstein's writes in TheStreet.com "Never trust clinical data from India"... More...
Also in this issue…
Amnog: Does a German Launch Make Sense?
Combination Drugs: Recalibrating the Pharma Revolution
GSK Announces $50-million Innovation Fund in Canada

Product Profile
NNIT

GxP Cloud - business enablement for Life Sciences only
NNIT has built an enhanced cloud allowing Life Science companies to enjoy all the benefits from cloud computing and still fulfill the GxP requirement.
Read more


 

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing magazines@superfill.com or by mail
at Advanstar Communications Inc., Bridgegate Pavilion, 4A Chester Business Park, Wrexham Road, Chester, CH4 9QH, UK